Reducing Recurrence of C. difficile Infection

Michael G Dieterle; Vincent B Young

doi:10.1016/j.cell.2017.03.039

Reducing Recurrence of C. difficile Infection

Cell. 2017 Apr 20;169(3):375. doi: 10.1016/j.cell.2017.03.039.

Authors

Michael G Dieterle¹, Vincent B Young²

Affiliations

¹ University of Michigan Medical School, Ann Arbor, MI 48103, USA. Electronic address: mdieterl@med.umich.edu.
² University of Michigan Medical School, Ann Arbor, MI 48103, USA. Electronic address: youngvi@med.umich.edu.

PMID: 28431238
DOI: 10.1016/j.cell.2017.03.039

Abstract

Clostridium difficile infection (CDI) is facilitated by alteration of the microbiome following antibiotic administration. Antimicrobial therapy directed against the pathogen can treat CDI. Unfortunately, ∼20% of successfully treated patients will suffer recurrence. Bezlotoxumab, a human monoclonal antibody, binds to C. difficile toxin B (TcdB), reducing recurrence presumably by limiting epithelial damage and facilitating microbiome recovery.

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antibodies, Neutralizing / therapeutic use*
Broadly Neutralizing Antibodies
Clostridioides difficile / physiology*
Enterocolitis, Pseudomembranous / drug therapy*
Gastrointestinal Microbiome
Humans
Intestines / drug effects
Secondary Prevention

Substances

Antibodies, Monoclonal
Antibodies, Neutralizing
Broadly Neutralizing Antibodies
bezlotoxumab